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Autologous stem cell transplantation (ASCT) for multiple
myeloma (MM) offers a unique setting to explore the role
of immunotherapy in eradicating residual disease. A chal-
lenge to developing an effective anti-tumor immune
response is overcoming the suppressive effect of inhibitory
pathways, including the PD-1/PDL1 pathway. We are con-
ducting a clinical trial in which MM patients are treated
with an anti-PD1 antibody (CT-011) alone (Cohort 1) and in
combination with a dendritic cell/myeloma fusion cell
vaccine (Cohort 2) following ASCT. To date, 27 patients have
been enrolled into Cohort 1, in which patients receive three
infusions of CT-011 at doses of 3 mg/kg given at 6 week
intervals beginning 1-3 months following ASCT. Mean age
of the patients is 57 years; 61% are male. Twelve patients
have received at least two infusions of CT-011. CT-011 has
been well tolerated, with possibly related adverse events
consisting of transient grade 1-2 leukopenia, diarrhea,
fatigue, arthralgia, rash, and peri-orbital edema. One
patient developed grade 3 neutropenia, which resolved
after two days without growth factor. Immunologic
response was determined by quantifying circulating tumor
reactive T cells prior to each dose of CT-011 and at 1, 3, 6
months following the last infusion, as deﬁned by the
percentage of T cells expressing IFNg in response to ex vivo
exposure to autologous tumor lysate. Four patients have
completed 6 months of follow up, and are evaluable for
immune response. CT-011 was associated with the dramatic
expansion of myeloma speciﬁc T cells. Mean percentage of
circulating tumor reactive CD4þ and CD8þ T cells increased
from 1.5 and 1.96 respectively prior to the ﬁrst infusion of
CT-011, to 4.26 and 8.28 respectively 1 month following the
third infusion. As determined by tetramer staining in the
subset of patients who are HLA A2.1, CT-011 resulted in
a mean 9 fold expansion of T cells speciﬁc to the MUC1
antigen. Notably, immunologic response to CT-011 persists
at 6 months following completion of therapy. Clinical
response, as determined by time to disease progression,
will be determined with longer follow up. We have initi-
ated enrollment to Cohort 2, in which patients will be
vaccinated with an autologous DC/myeloma fusion vaccine
1 week prior to each dose of CT-011. These data demon-
strate that CT-011 results in the expansion of tumor reac-
tive lymphocytes in the early post-transplant period,
providing an ideal platform for combination with a tumor
vaccine.2
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Introduction: Histone deacetylase inhibitors (HDACi) are an
important class of anti-cancer agent and have been shown by
us and others to attenuate experimental GVHD in multiple
murine models. We and others have shown that HDACi
reduce proinﬂammatory cytokines, modulate APC functions
through induction of IDO in a STAT-3-dependent manner,
and increase Treg numbers (PNAS 2004; JCI 2008; Nat Med
2007). We have now translated our experimental observa-
tions from murine models into a ﬁrst-in-human clinical trial
to test the hypothesis that HDAC inhibition is safe and
reduces GVHD severity in patients undergoing matched
related donor (MRD) reduced intensity conditioning (RIC)
HSCT.
Methods: 45 subjects were enrolled from two centers in
a phase I/II trial that added the HDACi, vorinostat 100mg BID,
to a standard GVHD prophylaxis regimen (tacrolimus and
MMF). The primary endpoint was the incidence of day 100
grade 2-4 acute GVHD with a risk of 25% compared with 42%
in historical controls. The RIC regimen consisted of ﬂudar-
abine 40 mg/m2 (4 days) and busulfan 3.2 mg/kg (2 days).
Based on our experimental observations, we obtained 4
blood samples from study subjects: (1) prior to study drug
administration (pre-therapy), (2) day 1, (3) day 30, and (4)
day 100 to perform correlative studies.
Results: Vorinostat was safe, tolerable, and feasible to
administer after MRD RIC HSCT. All study subjects have
engrafted and there have been no DLTs. Donor chimerism
was 95%, 97.5%, and 100% by day 30, 100 and 365, respec-
tively. We performed pharmacokinetic studies of vorinostat
in blood samples on day 1 at: pre-dose (immediately before
the ﬁrst dose of the day), 0.5, 1, 2, 3, 4, 6, and 12h (immedi-
ately before the second dose of the day). Themean half-life of
study subjects was 1.8h (1.3-2.3h) resulting in a mean AUC,
Cmax and Tmax 2.51.4mM*h, 0.491.0mM, and 2.6h (1-4h),
respectively. We then investigated the pharmaco-dynamic
effects of HDAC inhibition on day 30 after BMT. Study
patients demonstrated enhanced H4 acetylation in PBMCs
compared with historical controls (P¼0.009), suggesting that
HDAC enzymes were inhibited. We also determined the
functional impact of HDACi on PBMCs from study patients
and found that HDACi acetylated STAT-3 (P¼0.005),
enhanced IDO expression (P<0.0001), and reduced in vivo
TNF-a (P¼0.039) and IL-6 (P¼0.048) secretion and also ex
vivo following LPS stimulation (P<0.05). Study patients
showed increased numbers of CD4þCD25þCD127- T cell
population (Treg) (P¼0.04) and Foxp3þ expression by qPCR
(P¼0.006). Consistent with experimental and laboratory
data, the incidence of GVHD at day 100 (primary endpoint)
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3-4) with no increase in relapse (17% at 1-year).
Conclusions: These data demonstrate translation of our
experimental observations into a novel proof-of-concept
phase I/II clinical trial of vorinostat in reducing the incidence
of GVHD.3
Inhibition of c-Rel Activity Prevents Graft-Versus-Host
Disease without Compromising Tumor Immunity
Yusuke Shono 1, Andrea Z. Tuckett 1, Hsiou-Chi Liou 2,
Gregoire Altan-Bonnet 3, Jennifer J. Tsai 1, Odette M. Smith 1,
Mallory L. West 1, Natalie V. Singer 1,
Marcel R.M. van den Brink 4, Johannes L. Zakrzewski 5.
1 Department of Immunology, Memorial Sloan-Kettering
Cancer Center, New York, NY; 2 Department of Immunology,
Weill-Cornell Medical Center, New York, NY; 3 Department of
Computational Biology and Immunology, Memorial Sloan-
Kettering Cancer Center, New York, NY; 4 Department of
Medicine and Immunology, Memorial Sloan-Kettering Cancer
Center, New York, NY; 5 Department of Pediatrics, Memorial
Sloan-Kettering Cancer Center, New York, NY
Using methods to inhibit the NFkB family member c-Rel,
a transcription factor that upon antigen receptor triggering
regulates lymphocyte survival and proliferation, we devel-
oped a novel strategy to diminish alloactivation of T cells
while preserving GVT activity.
We investigated the role of c-Rel during GVHD in MHC
mismatched as well as MHC matched, minor antigen mis-
matched murine HSCT models. c-Rel-/- T cells caused signif-
icantly less GVHD than normal T cells, as determined by
survival (p<0.001), clinical GVHD score (p<0.01), and
histopathology of GVHD target organs. On day 3 post trans-
plant, proliferation and activation of c-Rel-/- T cells was
impaired (p<0.001 CFSElow/high ratio; p<0.01 CD25þ donor
cells) and pSTAT5 expression was decreased (p<0.05),
resulting in less expansion of donor derived effector Tcells by
day 7 after transplant (p<0.001). Unexpectedly, serum levels
of IL-2 were increased on day 7, likely secondary to decreased
pSTAT5-mediated negative feed back on IL-2 secretion. In
addition, IL-21, a target gene of c-Rel and negative regulator
of IL-2, was decreased (p<0.05) in recipients of c-Rel-/- T cells
during early GVHD. By day 14 post BMT we observed
increased numbers of donor derived Tregs with increased
CD25 expression in recipients of c-Rel-/- T cells (p<0.05),
suggesting that the increased IL-2 levels primarily beneﬁted
the expansion of Tregs. Consistent with this hypothesis, in
vivo depletion of donor Tregs in recipients of c-Rel inhibited
Foxp3DTR transgenic T cells exacerbated GVHD.
We next evaluated if c-Rel deﬁcient T cells were able to
mediate antitumor activity. We challenged allogeneic HSCT
recipients with either a liquid tumor (A20) or a solid tumor
(RENCA) and found that GVT activity in c-Rel-/- T cells
recipients was intact in the absence of GVHD, resulting in
signiﬁcantly improved survival compared to recipients of
wildtype T cells (p<0.001 A20; p<0.01 RENCA). Using
syngeneic GVT models with EL4 as well as B16 we could
demonstrate strong anti-tumor activity of c-Rel deﬁcient
polyclonal T cells targeting EL4 as well as melanoma antigen-
speciﬁc pmel-1 transgenic T cells in the absence of T cell
alloactivation, reinforcing the notion of separation of GVHD
from GVT activity through inhibition of c-Rel signaling.
The potential for clinical translation of our approach is
highlighted by a series of experiments testing the efﬁcacy of
a recently developed Pyrimidinetrione-based small molecule
c-Rel inhibitor compound. Using T cells that were pre-incubated with this c-Rel inhibitor, we reproduced our above
described effects on GVHD and antitumor activity (Figure 1).
Taken together, our ﬁndings identify c-Rel as a promising
target for the development of a clinical strategy to prevent
GVHD while preserving GVT activity, and to possibly even
enable adoptive T cell therapy across MHC barriers that
would be incompatible with a conventional transplant
approach.
Figure 1. Pre-incubation of donor T cells with a c-Rel antagonist prevents
GVHD while preserving GVT activity.
(A-C) Lethally irradiated (8.5Gy) BALB/c recipients received 5  106 WT B6
TCD-BM cells with 0.5  106 WT B6 CD5+ T cells after 24 hours of pre-
incubation with a c-Rel antagonist. Control mice received 5  106 WT B6 TCD-
BM cells with 0.5  106 WT B6 CD5+ T cells that were pre-incubated with
empty vehicle control solution. On day 0, HSCT recipients were challenged
with 0.25  106 luciferase-expressing A20-TGL tumor cells. Data are repre-
sentative of at least two independent experiments; n ¼ 5-8. Error bars indicate
SEM. *P<0.05; ***P<0.001. (A) Survival curve. (B) Body weight changes. (C)
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Historical data are conﬂicting as to whether superior
outcomesoccurwith cyclophosphamide (CY)þTBI compared
to oral busulfan (BU)-based myeloablative conditioning
regimens. IV BUwith orwithout pharmacokineticmonitoring
is better tolerated than oral BU. To testwhethermyeloablative
IVBU-basedconditioning regimens result in similaroutcomes
to traditional TBI-based conditioning, we conducted
a prospective multi-center cohort study comparing these 2
approaches in patients with myeloid malignancies (AML,
MDS, CML) undergoing matched related or unrelated donor
blood or marrow transplants. All patients received myeloa-
blative conditioning intensity (IV BU (>9mg/kg) plus Cy (60
mg/kg) or ﬂudarabine (80mg/m2); TBI (500cGy in a single
fraction or 800 cGy fractionated) plus Cy (60 mg/kg) or
etoposide (30 mg/kg)) and calcineurin-inhibitor based
